Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
The Chief Medical Officer at Baptist Health addressed the sickness in the community that we are seeing this time of year.
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
“People's phones are out when urinating and defecating, exposing the phones to bacteria,” says Dr. Suraj Saggar, chief of ...